
[email protected]
Jerry Avorn
Professor of Medicine at Harvard Medical School; Studies the Intended & Adverse Effects of Prescription Drugs
Dr. Avorn, Alosa Health’s President of the Board and Chief Clinical Consultant, is Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. An internist, geriatrician, and drug epidemiologist, he studies the intended and adverse effects of prescription drugs, physician prescribing practices, and medication policy.
The division he leads includes faculty with backgrounds in internal medicine and its subspecialties, geriatrics, epidemiology, health services research and policy, biostatistics, and computer science. His major areas of research include the scientific, policy, and social factors that shape physicians’ drug choices; the identification and prevention of adverse drug effects; medication compliance by patients; programs to improve the appropriateness of prescribing and drug taking; and pharmaceutical cost-effectiveness analysis. Dr. Avorn pioneered the “academic detailing” approach to continuing medical education, in which non-commercial, evidence-based information about drugs is provided to doctors through educational outreach programs run by public-sector sponsors. Such programs are now in use in the U.S., Canada, Australia, and Europe.
Dr. Avorn did his undergraduate training at Columbia University in 1969, received the M.D. from Harvard Medical School in 1974, and completed a residency in internal medicine at the Beth Israel Hospital in Boston. He has served as president of the International Society for Pharmaco-Epidemiology and is a member of the Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Dr. Avorn is the author or co-author of over 275 papers in the medical literature on medication use and its outcomes and is one of the most highly-cited researchers working in the area of medicine and the social sciences. His book, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, was published by Knopf in 2004 and is now in its 11th printing.
Related Speakers View all
![]() |
Dr. Lloyd Minor
Scientist, Surgeon & Academic Leader; Dean of the St...
|
![]() |
Bennett Levitan
Director of Epidemiology at Janssen R&D Pharmaceutic...
|
![]() |
Dr. Paul Offit
Director of the Vaccine Education Center, Children's...
|
![]() |
Toby Cosgrove
Former CEO & President at Cleveland Clinic
|
![]() |
Dr. Francis Collins
Director of the National Human Genome Research Insti...
|
![]() |
Ken Dychtwald
Founder & CEO of Age Wave; Gerontologist & Expert on...
|
![]() |
Aubrey de Grey
Biomedical Gerontologist; Chief Science Officer of S...
|
![]() |
Maddy Dychtwald
Co-Founder & Senior VP of Age Wave, Author & Changin...
|
![]() |
Stephanie Lheureux
Clinician Investigator & Medical Oncologist at Princ...
|
![]() |
Chris Johnson, MD
Physician, Expert Speaker on the Opioid Crisis, Foun...
|
![]() |
Terry Fulmer
President, The John A. Hartford Foundation
|
![]() |
Peter Hotez
Dean & President of the National School of Tropical ...
|
![]() |
Paul Hastings
Chairman and Chief Executive Officer, OncoMed Pharma...
|
![]() |
Dr. Eric Coleman
Professor of Medicine & Head of the Division of Heal...
|
![]() |
Lisa Cooper
Professor, John Hopkins University of Medicine
|
![]() |
Henry Greely
Professor of Law & Genetics at Stanford University
|
|
Pinchas Cohen
Dean, University of Southern California Davis School...
|
![]() |
Christopher Austin
CEO-Partner at Flagship Pioneering
|
![]() |
Neal E. Cutler
President of American Institute of Financial Geronto...
|
![]() |
Dr. Joel Selanikio
Award-Winning Physician, Health & Technology Activis...
|